Analytical Data
-
Gene name
PPARG
- Application
-
Alternative Names
PPARG;NR1C3;Peroxisome proliferator-activated receptor gamma
-
Species
Human
-
Source
E. coli
-
Tag
N-6His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P37231
-
Expression Region
157~274aa
-
Molecular Weight
15kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
PPARG, or Peroxisome Proliferator-Activated Receptor Gamma, is a nuclear receptor that plays a crucial role in regulating glucose and lipid metabolism, making it a significant target in the study of metabolic disorders such as obesity and type 2 diabetes. As a transcription factor, PPARG influences the expression of genes involved in fatty acid storage and glucose metabolism, thereby mediating effects on insulin sensitization and inflammation. Research into recombinant PPARG proteins has gained prominence due to their potential therapeutic applications in metabolic diseases, as well as their role in adipogenesis and cardiovascular health. Given that PPARG agonists, such as thiazolidinediones, have been used clinically, understanding the structural and functional properties of recombinant PPARG can lead to the development of more effective and targeted treatments. Additionally, studies of PPARG's interaction with various ligands can provide insights into the molecular mechanisms underlying its regulatory functions, further enhancing the capacity for rational drug design. Overall, the exploration of recombinant PPARG is essential for unraveling its complex biological roles and for advancing therapeutic strategies in managing metabolic diseases.
